For the purpose of summary, principal findings of interest to this review are presented and many sub-analyses excluded. Reference exposure group was human insulin unless otherwise noted *number of people with neoplasms rather than count of neoplasms ** incidence rate ratio not relative risk (IRR), HR is hazard ratio, *** note in contrast to other models, for these reference exposure is glargine only. Any glargine use = use of glargine as only insulin or in combination with non-glargine insulins. Glargine only= glargine is the only insulin use recorded in data. ≈ indicate approximate values 1900 1901 1902 1903 1904 1905 1906 1907 1908 1909 1940 1941 1943 1944 1945 1946 1948 1949 1951 1952 1953 1954 1955 1958 1960 1961 1962 1963 1965 1966 1968 1969 1970 1971 1972 1973 1974 1975 1976 1977 1978 1980 1981 1982 1983 1984 1985 1986 1987 19881 19882 19889 20971 20972 20973 20974 51181 78951 1990 1991 1992 20920 The date of cancer onset was set to the earliest of: the first inpatient or second outpatient diagnosis.
Supplementary
Patients were permitted to contribute only one incident cancer event.
